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Diabetes mellitus is a chronic disease that can affect any organ or system of the body. Diabetes mellitus has long 
been considered as one of the factors causing Candida vaginitis and has the potential to affect sexual function in 
women. Infectious diseases are more prevalent in individuals with Diabetes Mellitus. One of the problems of 
women with diabetes is resistant vulvovaginitis, which is related to some factors such as neuropathy, hypergly-
cemia, allergy and atopy. Women’s interest in, satisfaction with, and ability to participate in sexual activity may be 
influenced globally by the effect of diabetes on their overall health, physical and mental functioning, and inter-
personal relationships. Additionally, sexual function may be adversely affected by diabetes medications or other 
health interventions. This manuscript is a comprehensive review on vulvovaginal infections in diabetic patients. 
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Diabetes is a chronic disease, which occurs 
when the pancreas does not produce enough 
insulin, or when the body cannot effectively use 
the produced insulin. This leads to an increased 
concentration of glucose in the blood (hyper-
glycemia). Type 1 diabetes (previously known as 
insulin-dependent or childhood-onset diabetes) 
is characterized by a lack of insulin production. 
Type 2 diabetes (formerly called non-insulin-
dependent or adult-onset diabetes) is caused by 
the body’s ineffective use of insulin. It often re-
sults from excess body weight and physical in-
activity. Gestational diabetes is hyperglycemia 
that is first recognized during pregnancy. 346 
million people worldwide have diabetes. In 
2004, an estimated 3.4 million people died from 
consequences of high blood sugar. WHO pro-
jects that diabetes death will double between 
2005 and 2030 (WHO, 2011). Diabetes is char-
acterized by elevated morbidity and mortality. 
Diabetes represents an economic burden, with 
serious implications for the public health sys-
tems. Accordingly, the need of effective tools 
aimed to the prevention of its chronic compli-
cations is urgent and cannot be deferred 
(Lavery et al. 1998, 157–62). 
Besides the classical complications of the dis-
ease, DM has been associated with reduced re-
sponse of T cells, neutrophil function, and dis-
orders of humoral immunity (Geerlings and 
Hoepelman 1999, 259–65; Peleg et al. 2007, 3–
13). Consequently, DM increases the suscepti-
bility to infections, both the most common 
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ones as well as those that almost always affect 
only people with DM (e.g. rhino cerebral mu-
cormycosis) (Peleg et al. 2007, 3–13). Such in-
fections, in addition to the repercussions asso-
ciated with its infectivity, may trigger DM com-
plications such as hypoglycemia and ketoacido-
sis. Infectious diseases are more prevalent in 
individuals with DM. The main pathogenic 
mechanisms are hyperglycemic environment in-
creasing the virulence of some pathogens; lower 
production of interleukins in response to infec-
tion; reduced chemotaxis and phagocytic activi-
ty, immobilization of polymorphonuclear leu-
kocytes; glycosuria, gastrointestinal and urinary 
dysmotility. Some infections usually affect only 
diabetic persons, such as malignant external oti-
tis, rhino cerebral mucormycosis, and gangre-
nous cholecystitis. In addition to being poten-
tially more serious, infectious diseases in DM 
may result in metabolic complications such as 
hypoglycemia, ketoacidosis, and coma (Casquei-
ro, Casqueiro and Alves 2012, S27-36). 
Diabetes causes short-term and long-term 
complications and usually its long-term compli-
cations develop 5 to 10 years after the diagnosis 
of both types of the disease (Smeltzer, S. Bare 
2000). One of its long-term complications is a 
neurological complication that includes a disor-
der of sexual functioning. The autonomic sys-
tem causes a wide range of disorders in all sys-
tems of our body including the urinary-sexual 
system. It can be said that sexual dysfunction 
develops frequently as a complication among 
these patients (Chu and Edelman 2002, 60–66). 
Neuropathy, vascular impairment, and psycho-
logical complications are involved in decreased 
libido, low arousal, decreased vaginal lubrica-
tion, orgasmic dysfunction, and dyspareunia 
among women with diabetes.  
Moreover, one of the problems of women with 
diabetes is resistant vulvovaginitis, which is re-
lated to some factors such as hyperglycemia, al-
lergy and atopy. One of the most common 
pathogens associated with this condition is 
Candida spp. (Malazy et al. 2007, 399–404). 
 
Material and methods 
The following sources were searched for the 
original study: The Cochrane Library, MED-
LINE, EMBASE and the Cochrane sexually 
transmitted disease (2000-2014). Selection crite-
ria were: 
 Randomized controlled trials pub-
lished in any language; 
 Women (age 16 years or over) with 
uncomplicated vulvovaginal candidiasis; 
 The vulvovaginal candidiasis to be 
made mycological (i.e. positive culture 
and/ or microscopy for yeast); 
 The primary outcome measure was 
clinical cure. 
 
Data collections and analysis 
Two reviewers screened titles and abstract of 
the electronic search results and full text of po-
tentially relevant papers. Two reviewers per-
formed independent duplicate abstraction. Dis-
agreements regarding trial inclusion or data ab-
straction were resolved by discussion between 
the reviewers. Odds ratios were pooled using 
the fixed effects models (except for two anal-
yses when random effects models were used 
because of potentially important heterogeneity).   
  
Normal vaginal flora 
Anatomically, the female genital tract is consti-
tuted by a succession of cavities that communi-
cate with exterior through the vulvar cleft. Vag-
inal microflora undoubtedly presents one of the 
most of important defense mechanism for the 
reproductive function, maintaining the envi-
ronment healthy and preventing the prolifera-
tion of microorganisms, stranger to the vagina 
(Linhares, Giraldo and Baracat, 370–74). The 
different components of the vaginal ecosystem 
have been observed on the microscope and af-
terwards, identified through culture-specific 
techniques (Larsen and Monif 2001, e69-77). 
However, more recently, identification tech-
niques for independent bacteria in the means of 
culture have revolutionized the study of micro-
organisms. The use of amplification, cloning 
techniques and subsequent analysis of sequenc-
es of bacterial genes (genes that codify for bac-
terial rRNA 16S) in sample of vaginal fluid have 
allowed the identification of the majority of 
common species of Lactobacilli and other mi-
croorganisms.  Thus, these techniques have 
demonstrated that Lactobacilli spp. do not al-
ways correspond to the dominant species in the 
vagina of healthy women. Besides that, vagina 
environment inhabitants until then unknown 
have been identified (Zhou et al. 2004, 2565–
73; Fredricks, Fiedler and Marrazzo 2005, 
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1899–1911). Although vaginal bacterial species 
of healthy women have been initially identified 
as Lactobacillus acidophilus, this knowledge 
represents a simplification, since in women 
whose flora is dominated by Lactobacillus, the 
more frequently detected species through genic 
amplification are L. crispatus and L. inners 
(Zhou et al. 2004, 2565–73; Fredricks, Fiedler 
and Marrazzo 2005, 1899–1911) or L. crispatus 
and L.gasseri (Verhelst et al. 2004, 16). Other 
species as. L. jensenii, L. gallinarum and L. 
vaginalis have also been identified in some 
women. A study on vaginal flora accomplished 
in three continents using method of bacterial 
genes analysis showed that dominant species 
were the same in each region: L. crispatus, 
L.gasseri and L. jensenii (Pavlova et al. 2002, 
451–59) Besides, that, the same study observed 
that, in some women, the normal ecosystem 
was maintained in the absence of Lactobacillus; 
in one woman Atopobium vaginae was identi-
fied as the dominant microorganism in the flora 
and, in two other woman, the bacteria Ato-
pobium, Megasphaera and Leptotrichia were all 
lactic acidic producers similarly Lactobacillus. 
(Zhou et al. 2004, 2565–73; Rodriguez Jovita et 
al. 1999, 1573–76). Therefore, other bacteria, 
not only by Lactobacillus, may keep the vagi-
na’s acidic environment, known as an important 
defense mechanism against the proliferation of 
pathogens. Characteristic of vaginal microbial 
flora is the presence of biofilms. Biofilms are 
formed by colonies of microorganisms that ad-
here among themselves and cover a solid sur-
face. Biofilms have already been identified in 
the surface of vaginal cells, more known in 
women with bacterial vaginosis, where species 
of Gardnerella vaginalis and Atopobium pre-
dominate (Swidsinski et al. 2005, 1013–23). The 
occurrence of species of Lactobacilli producers 
of hydrogen peroxide, which possess a defense 
activity against pathogens, seems to be less fre-
quent in African-American women (Antonio, 
Hawes and Hillier 1999, 1950–56). Studies sug-
gest that for bacterial vaginosis-free women, the 
vaginal pH is higher in African-American wom-
en (Stevens-Simon et al., 168–72) they suggest 
also that such differences are valid only for 
women whose vaginal microflora is not domi-
nated by Lactobacillus (Royce et al. 1999, 96–
102; Fiscella and Klebanoff 2004, 747–50). The 
composition of the vaginal flora is not constant, 
suffering variations in response to exogenous 
and endogenous factors (Priestley et al. 1997, 
23–28; David A. Eschenbach et al. 2001, 913–
18). These factors include the different phase of 
menstrual cycle, gestation, use of contracep-
tives, frequency of sexual intercourse, use of 
showers or deodorant products, use of antibiot-
ics or other medications with immune-
suppressive properties. Alterations occurring in 
the vaginal environment may increase or de-
crease the selective advantages for specific mi-
croorganisms. For example, studies have related 
the loss of Lactobacillus to sexual intercourse 
or the use of antibiotics (Schwebke, Richey and 
Weiss2 1999, 1632–36). 
Nevertheless, another study has demonstrated 
that the sexual act without the use of condom 
had o effects upon the Lactobacillus, but in-
crease the level of Escherichia coli and faculta-
tive gram-negative bacilli (D A Eschenbach et 
al. 2000, 901–7). 
During the menstrual cycle, hormonal varia-
tions interfere in the substrate of different mi-
croorganisms; these variations lead to change s 
in vaginal ph. Yet the levels of Lactobacillus 
remain constant throughout the cycle, the non-
Lactobacillus bacteria increase during the pro-
liferative phase and the concentrations of Can-
dida albicans become higher in the pre-
menstrual period (Witkin 1987, 34–37). 
Candida albicans is tolerant to the acidic envi-
ronment, fund in approximately 10% to 20% of 
women in reproductive age. The concentration 
of the microorganism is low, so the woman car-
rier is asymptomatic. Nevertheless, event lead-
ing to a state of local immune-suppression, 
such as sexual intercourse or local induction of 
allergic response, create adequate conditions for 
the proliferation of the microorganism and fa-
cilitate the transformation into the shape of hy-
phae, more invasive (Witkin 1987, 34–37) Fur-
thermore, Candida albicans appears to be able 
to raise the pH from 4 to > 7, resulting in auto 
induction of yeast-hyphal transition as demon-
strated in study of Vylkova et al. (Vylkova et al. 
2011, e00055-11). When the hyphal form is 
predominant, it results in the emergence of 
symptomatic vaginitis.  The production of lactic 
acid may be essential for the maintenance of 
healthy ecosystem, regardless of the bacterial 
species that may be present in the vagina. Re-
sulting acidic pH prevents the excessive prolif-
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eration of potentially pathogenic microorgan-
isms. It is important yet to remember that the 
Lactobacillus dominance is beneficial for the 
host, since some species produce hydrogen 
peroxide and bacteriocins, factors that inhibit 
the proliferation of the other microorganisms. 
In addition to the protective effects of the en-
dogenous vaginal flora, the protection against 
potentially pathogenic microorganisms is done 
also by the local components of innate immuni-
ty and acquired immunity. The epithelial cells 
layer of the vagina constitutes the initial contact 
point between microorganism and host’s genital 
tract. These epithelial cells possess toll-like re-
ceptors (TRL) in their surface and, therefore, 
are important components of innate vaginal 
immunity (Quayle, 61–79). Vaginal cells also re-
lease molecules with potent non-specific anti-
microbial activity. A class of these molecules, 
known as defensives, include positively charged 
peptides that rapidly bind negatively charged 
bacterial surface (Linhares, Giraldo and Baracat, 
370–74). 
 
Vulvovaginal diseases in diabetic woman 
A. Candidiasis 
One of the problems of women with diabetes is 
resistant vulvovaginitis, which is related to 
some factors such as hyperglycemia, allergy and 
atopy. One of the most common pathogens as-
sociated with this condition is Candida albicans. 
Thus, most physicians begin antifungal therapy 
at the patient’s first visit, even without para-
clinical findings. The prevalence of Candida 
spp. vulvovaginitis and factors that cause dia-
betic women to be prone to this infection were 
analyzed in a study of B.  160 women with dia-
betes mellitus (mean age, 51 - 10 years; age 
range, 16–75 years) were enrolled. Ninety-four 
percent of the patients had type II diabetes 
mellitus and the remaining had type I. Seventy-
five percent of the participants received oral 
hypoglycemic drugs, 15% received insulin and 
the rest were given combination therapy (tab-
lets plus insulin). The mean duration of diabetes 
mellitus in these patients was 9 - 6 years (range, 
0.08–36 years). The subjects were mainly 
homemakers (92.5%), and the rest were work-
ers. There was sexual activity in 86.3% of the 
cases, and none in 13.7% of the cases. Twenty-
one percent of our patients had a history of al-
lergy (rhinitis, sinusitis or atopic dermatitis) 
(Malazy et al. 2007, 399–404). 
In this study, all subjects were asked to fill out 
prepared questionnaires on demographic char-
acteristics, type of diabetes mellitus, duration 
and type of its treatment, past history of allergy, 
methods of washing underwear (detergents, 
heat, etc.) and voiding after sexual intercourse, 
and vaginal examination was done for each par-
ticipant by a general physician. In addition, 
concentrations of fasting blood sugar, 2-hour 
postprandial blood sugar and glycosylated he-
moglobin were measured, and cultures of vagi-
nal discharge were performed.  
71% (113/160) of the women had clinical vagi-
nitis (fungal or bacterial), and 12.5% (20/160) 
had Candida vaginitis. Microscopic findings for 
Candida were positive in 12 patients, of whom 
two had Candida vaginitis. 
The prevalence of Candida vaginitis together 
with positive culture was 2.6% (4/160). After 
including the 10 patients with positive Candida 
culture together with other clinical vaginitis, the 
overall prevalence of Candida vaginitis based 
on positive culture was 8.8% (14/160). There 
was a significant statistical difference between 
either mean fasting blood sugar or educational 
level and infectious vaginal culture. There were 
no significant associations between positive cul-
ture and age, glycosylated hemoglobin, history 
of allergy, genital hygiene, and occupation, kind 
of treatment, and type or duration of diabetes. 
One of the complications experienced by dia-
betic patients is resistant and recurrent infec-
tions. Some believe that malfunctioning leuco-
cytes, especially in the presence of uncontrolled 
blood glucose levels (Wilson and Reeves 1986, 
478–84; Wilson, Tomlinson and Reeves, 37–40; 
Raith, Csató and Dobozy 1983, 557–64) cause 
the condition. Among the infections, vaginal 
inflammation or infection, especially fungal 
vaginitis, is more disturbing in severe hypergly-
cemic conditions (Foster 1998, 2060–81) The 
most common etiologic agent for this infection 
is the yeast (fungal) organism, usually Candida 
(Curry 1994, 689–700; Eckert et al. 1998, 757–
65; Smith 1998, 557–58; Moraes 1998, 165–69; 
Bornstein et al. 2001, 105–11). In a study by 
Eckert et al (Eckert et al. 1998, 757–65) Can-
dida was detected in 28% of cultures of vaginal 
discharge obtained during the initial visit of 
women with vaginitis; the remaining cultures 
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were for other organisms, such as sexually 
transmitted organisms. In this case, the authors 
believed that the causes of recurrent disease or 
resistance to therapy were false diagnosis of the 
pathogenic organism and unsuitable treatment 
(Eckert et al. 1998, 757–65). On the other hand, 
even when correct diagnosis had been made, 
background factors, especially those associated 
with systemic diseases like diabetes mellitus, 
caused treatment failure (Foster 1998, 2060–81; 
Smith 1998, 557–58). Researchers have stressed 
the importance of personal hygiene, history of 
infections and allergic diseases of the upper 
respiratory tract (nose, sinuses), and atopic 
dermatitis in the subject or the relative(s) in re-
current diseases or resistance to therapy 
(Moraes 1998, 165–69). 
In this study, the authors stated that there are 
no significant statistical differences or relation-
ship between positive vaginal Candida culture 
and type of diabetes mellitus, age, and glycosyl-
ated hemoglobin, duration of diabetes mellitus, 
history of allergy, occupation, genital hygiene 
and vaginal intercourse. Diabetes mellitus has 
long been considered as one of the factors 
causing Candida vaginitis (J D Sobel 1993, 153–
65; Scudamore, Tooley and Allcorn 1992, 260–
63). Different studies showed that symptomatic 
infection is more common in women with dia-
betes than in the normal population (J D Sobel 
1993, 153–65; Scudamore, Tooley and Allcorn 
1992, 260–63). The prevalence ranged from 
around 7% to more than 50% (Bohannon 1998, 
451–56; Sonck and Somersalo 1963, 846–52; 
Davis 1969, 40–45) and most of which was at-
tributed to Candida albicans (Duerr et al. 1997, 
252–56; Otero et al. 1998, 526–30). 
Two specialized clinics reported that the preva-
lence of vulvovaginitis caused by non-albicans 
species is around 10–20%, with Candida glabra-
ta dominating (Jack D. Sobel 1997, 1896–1903; 
Spinillo et al. 1992, 343–47). Sobel et al (J D 
Sobel et al. 1998, 203–11) stated that the prob-
able causes of higher non-albicans species: the 
short duration of use for oral or local anti-
Candida regimens; widespread use of over-the-
counter antifungal agents, most of which are 
used incorrectly or inadequately; and the pro-
longed use of antifungal compounds for the 
prevention of recurrent vulvovaginitis, which 
further intensifies the problem. 
The control of blood glucose levels and a suita-
ble antifungal therapy play an important role in 
controlling vaginal Candida spp. infection in di-
abetic women (Bohannon 1998, 451–56). In a 
study of 241 diabetic women, a significant sta-
tistical relationship existed between overall 
prevalence of vaginal infections (bacterial and 
fungal) and mean blood glucose level. In addi-
tion, it was suggested that glucose levels be 
maintained below 200 mg/dL to avoid dehy-
dration, caloric loss and glycosuria and to re-
duce the risk of infection. The authors also 
found a significant statistical difference between 
mean fasting blood sugar and infectious culture 
of vaginal discharge (p = 0.016). It did not find 
a significant statistical difference between gly-
cosylated hemoglobin and infectious vaginitis, 
because acute infections such as vaginitis often 
occur during the hyperglycemic state, but glyco-
sylated hemoglobin reflects the mean blood 
glucose level over the previous 3 months. 
Similar to the study by Mas Martin (R Goswami 
et al. 2000, 162–66) B also found that most of 
the patients with positive vaginal Candida cul-
ture (64%) were older than 45 years. Regarding 
the high prevalence of Candida vaginitis in re-
productive ages (Spinillo et al. 1992, 343–47; 
Deepti Goswami et al. 2006, 111–17) and our 
lack of knowledge about the prevalence of this 
condition in non-diabetic women with similar 
age groups (16–75 years), it is suggested that 
further evaluation be conducted to determine 
the cause. In any case, the incidence of symp-
tomatic infection 
is high among reproductive ages (18–44 years) 
(de Leon et al. 2002, 1). Although it was report-
ed that allergic rhinitis and recurrent Candida 
vaginitis were present concurrently in 70% of 
patients (Moraes 1998, 165–69) we did not find 
any relationship between Candida or non-
Candida vaginitis and history of allergy (sinusi-
tis, rhinitis or atopic dermatitis). According to 
our results, there was significant statistical dif-
ference between educational level and infec-
tious or positive vaginal Candida culture. 
Other factors involved in the pathogenesis of 
Candida vulvovaginitis include lifestyle factors. 
Although vulvovaginal candidiasis is more fre-
quent among sexually active women (during the 
second decade of life) (de Leon et al. 2002, 1) it 
is not considered as a sexually transmitted dis-
ease (Jack D. Sobel 1997, 1896–1903) Candida 
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accounts for 20–50% of the normal vaginal flo-
ra of asymptomatic healthy women (Geiger, 
Foxman and Sobel 1995, 304–7) and Candida 
vaginitis can even occur in single women. Natu-
rally, Candida is transmitted through vaginal 
sexual intercourse, as well as other modes of 
sexual contact. 
There is controversy about the frequency of 
sexual intercourse as a risk factor of vaginitis. 
However, some studies showed that oral sex 
increases the incidence of vulvovaginal candidi-
asis and that vaginal intercourse alone cannot 
change the Candida colonization rates in the 
vagina (Malazy et al. 2007, 399–404). 
Yeast development can be stimulated by glu-
cose and even be promoted to change to a 
more virulent stage. Pregnancy and ⁄ or diabetes 
increase(s) the adherence of C. albicans to vagi-
nal epithelial cells in vitro (Grigoriou et al. 
2006, 121–25). 
Women with type I diabetes had higher Can-
dida colonization rates than those with type II, 
even after adjusting for age, behavioral factors 
and HbA1c.10 Whether this is due to the diabe-
tes type or reflects the different distributions of 
Candida species by age or both remains unclear. 
With the oxidative killing ability of neutrophils 
hindered, diabetics may not be able to clear 
pathogens as efficiently as non-diabetics may. 
Hyperglycemic individuals may have increased 
risk for Candida colonization as their secretions 
contain glucose, which can serve as nutrients 
for Candida species. A fucose (6-deoxy-
galactose) vaginal epithelial cell receptor that 
aids in adhesion of Candida to vaginal epithelial 
cells was reported.30 Fucose acts as one form 
of the receptor site for Candida adhesion; 
therefore, increased Candida colonization may 
be proportional to the glucose level. However, 
glycaemia does not fully explain the observed 
increased risk of Candida colonization. Grigo-
riou et al (Malazy et al. 2007, 399–404) found 
an increased prevalence of vaginal candidiasis in 
diabetic patients compared with non-diabetic 
patients. Likewise, C. albicans was isolated sig-
nificantly more in diabetic patients than non-C. 
Albicans species (Yildirim, Kilic and Kalkanci 
2011, e463-7).  
Large proportion of vulvovaginal candidiasis 
(VVC) in diabetes is due to non–albicans Can-
dida species such as C. glabrata and C. tropical-
is. Observational studies indicate that diabetic 
patients with C. glabrata VVC respond poorly 
to azole drugs. It is evaluated the response to 
oral fluconazole and boric acidic vaginal sup-
positories in diabetic patients with VVC. 
112 consecutive diabetic patients with VVC 
were block randomized to receive either single-
dose oral 150-mg fluconazole or boric acidic 
vaginal suppositories (600 mg/day for 14 days). 
The primary efficacy outcome was the myco-
logical cure in patients with C. glabrata VVC in 
the two treatment arms. The secondary out-
comes were the mycological cure in C. albicans 
VVC, overall mycological cure irrespective of 
the type of Candida species, frequencies of 
yeast on direct microscopy, and clinical symp-
toms and signs of VVC on the 15th day of 
treatment. Intention-to treat (ITT; n = 111) and 
per protocol (PP; n = 99) analyses were per-
formed. 
C. glabrata was isolated in 68 (61.3%) and C. 
albicans in 32 (28.8%) of 111 subjects. Patients 
with C. glabrata VVC showed higher mycologi-
cal cure with boric acidic compared with flu-
conazole in the ITT (21 of 33, 63.6% vs. 10 of 
35, 28.6%; P = 0.01) and PP analyses (21 of 29, 
72.4% vs. 10 of 30, 33.3%; P = 0.01). The sec-
ondary efficacy outcomes were not significantly 
different in the two treatment arms in the ITT 
and PP analyses. 
Diabetic women with C. glabrata VVC show 
higher mycological cure with boric acidic vagi-
nal suppositories given for 14 days in compari-
son with single-dose oral 150-mg fluconazole. 
The 59.9% prevalence of C. glabrata infection 
observed in the current study confirms the 
findings of our earlier studies that non-albicans 
VVC is frequent in diabetic women (R 
Goswami et al. 2000, 162–66; Deepti Goswami 
et al. 2006, 111–17). De Leon et al (de Leon et 
al. 2002, 1) observed the 54% vaginal carriage 
rate of C. glabrata in type 2 diabetes. The com-
parable frequency of clinical symptoms and 
signs between diabetic women with C. glabrata 
or C. albicans infection is similar to that report-
ed by Geiger et al (Geiger, Foxman and Sobel 
1995, 304–7) in nondiabetic women. 
Increased prevalence of C. glabrata infection in 
diabetic women has clinical relevance because 
poor therapeutic response and innate resistance 
to azoles has been reported for C. glabrata 
VVC in nondiabetic women (Vermitsky and 
Edlind 2004, 3773–81) Similar information is 
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lacking in diabetic subjects, as they are often 
excluded in antifungal efficacy studies (Deepti 
Goswami et al. 2006, 111–17) Poor mycological 
cure in diabetic women with C. glabrata VVC 
to single-dose oral 150-mg fluconazole, ob-
served in the current study, is in accordance 
with our earlier case-control study (Deepti 
Goswami et al. 2006, 111–17). In the current 
study, the higher mycological cure (72.4%) to 
boric acidic therapy in diabetics with C. glabrata 
VVC is similar to that reported in nondiabetic 
individuals.   
Boric acidic or boracic [B (OH) 3] is a weak 
acidic, and its mode of antifungal action is not 
clear. Shiohara and Tasker (15) proposed that 
its acidic properties lead to disruption of the 
fungal cell wall. The cause of increased C. gla-
brata isolation in diabetic women is not clear 
but may involve frequent use of antifungal 
drugs leading to its reduced susceptibility to az-
oles (Ruhnke 2006, 495–504) and consequent 
polarization/homing in diabetic women. Feng 
et al (Feng et al. 2005, 445–50) reported lesser 
susceptibility of C. glabrata in comparison with 
Albicans to β-defensins, natural cationic antimi-
crobial/antifungal peptides expressed in human 
epithelia. In diabetic milieu, β-defensins expres-
sion is reduced (Froy et al. 2007, 796–802). Re-
duced expression of defensins in association 
with resistance of C. glabrata to fungicidal ac-
tivity of drugs like fluconazole may also explain 
the high prevalence of C. glabrata VVC in dia-
betic women. Boric acidic therapy could be 
considered as the frontline therapy for treating 
VVC in diabetic women because it is effective 
against both C. albicans and C. glabrata com-
pared with fluconazole, which is effective 
against C. albicans only (Ray et al. 2007, 312–
17). 
Sertaconazole nitrate is a new topical broad-
spectrum antifungal that was developed to pro-
vide an additional agent for the treatment of 
superficial cutaneous and mucosal infections. 
Sertaconazole has been tested in vitro against 
clinical and laboratory isolates of the most 
common fungi present in superficial tinea and 
Candida infections. Sertaconazole is effective 
against a broad spectrum of organisms that 
cause superficial cutaneous fungal infections. 
Clinical trials with Sertaconazole nitrate cream 
2% show efficacy in the treatment of superficial 
cutaneous fungal infections (Zsolt I. 2002, 29-
32). In European clinical studies of other der-
matomycoses caused by Candida spp., 
Sertaconazole was shown to be superior to oth-
er azoles and terbinafine. 
Sertaconazole nitrate has been tested with a va-
riety of in vitro methods, all of which show 
fungistatic activity against dermatophytes and 
fungicidal and fungistatic activity against yeasts 
(Carrillo-Muñoz et al. 2003, 248–51). 
In a similar study, Day (Grossman and Day 
2005, P128) showed that over a 48-h exposure 
period, approximately 38% of the applied dose, 
or 800 Ag, penetrated the skin. These results 
are considerably higher than the concentrations 
(MICs) required in susceptibility studies to 
eradicate fungal growth in vitro. Thus, a short 
course of treatment with Sertaconazole for 4 
weeks will give ratios of Cmax/MIC N1000 for 
dermatophytes and Candida. This level of ex-
posure should be sufficient to obtain successful 
mycological cure rates of the major dermato-
phytes and yeas that cause superficial fungal in-
fections; however, at present, there is insuffi-
cient data relating clinical outcome to drug ex-
posure and MIC to allow us to assign a predic-
tive value to these parameters. In immunocom-
petent patients, the majority of uncomplicated, 
superficial mycoses are yeast and tinea infec-
tions, caused mainly by Candida spp. and der-
matophytes, respectively (Pfaller and Sutton 
2006, 147–52). 
The most common vulvovaginal symptom es-
pecially during candidiasis include irritation, 
burning, erythema and sometimes dyspareunia 
(Lewis et al. 2010, 1598–1607). In particular 
itching is reported as the more discomfort 
symptom (Nowosielski and Skrzypulec-Plinta 
2011, 2532–45). 
 
B. Sexual / Libido diseases 
Diabetic women often deal with low sexual de-
sire, orgasmic dysfunction, dyspareunia, and 
sexual aversion along with decreased lubrication 
often related to neuropathy.  
Nerve problems can occur in every organ sys-
tem, including the digestive tract, heart, and sex 
organs. 
About 60 to 70 percent of people with diabetes 
have some form of neuropathy. People with di-
abetes 
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can develop nerve problems at any time, but 
risk rises with age and longer duration of diabe-
tes. The 
highest rates of neuropathy are among people 
who have had diabetes for at least 25 years. 
Hyperglycemia and oxidative stress also con-
tribute to the abnormal glycation of nerve cell 
proteins and the inappropriate activation of 
protein kinase C, resulting in further nerve dys-
function and ischemia.  
However, more recent large epidemiological 
studies conducted on women in the United 
States, Brazil, and Australia did not find a sig-
nificant relationship between diabetes, desire, 
arousal, or orgasm. In diabetic women, hyper-
tension or the use of hypertensive drugs seem 
to be associated with orgasm and lubrication 
dysfunction as well as decreased sexual interest. 
Stress urinary incontinence is negatively associ-
ated with all aspects of women’s sexual dys-
function (sexual interest, desire, arousal, lubri-
cation, and orgasm), and is positively correlated 
with dyspareunia and vaginismus (Lewis et al. 
2010, 1598–1607). 
Sexual function was examined in a cross-
sectional cohort of ethnically diverse women 
aged 40 to 80 years using self-administered 
questionnaires. Multivariable regression models 
compared self-reported sexual desire, frequency 
of sexual activity, overall sexual satisfaction, and 
specific sexual problems (difficulty with lubrica-
tion, arousal, orgasm, or pain) among insulin-
treated diabetic, noninsulin-treated diabetic and 
nondiabetic women. Additional models as-
sessed relationships between diabetic end-organ 
complications (heart disease, stroke, renal dys-
function, and peripheral neuropathy) and sexual 
function. 
Among the 2,270 participants, mean SD age 
was 55 ± 9.2 years, 1,006 (44.4%) were non-
Latina white, 486 (21.4%) had diabetes, and 139 
(6.1%) were taking insulin. Compared to 19.3% 
of non-diabetic women, 34.9% of insulin-
treated diabetic women (adjusted OR [95%CI] 
=2.04[1.32–3.15] and 26.0% of non-insulin-
treated diabetic women (adjusted OR [95%CI] 
=1.42[1.03–1.94]) reported low overall sexual 
satisfaction. Among sexually active women, in-
sulin-treated diabetic women were more likely 
to report problems with lubrication (OR 
[95%CI] =2.37[1.35–4.16]) and orgasm (OR 
[95%CI] =1.80[1.01–3.20]) than nondiabetic 
women. Among all diabetic women, end-organ 
complications such as heart disease, stroke, re-
nal dysfunction, and peripheral neuropathy 
were associated with decreased sexual function 
in at least one domain. Compared to nondiabet-
ic women, diabetic women are more likely to 
report low overall sexual satisfaction. Insulin-
treated diabetic women also appear at higher 
risk for problems such as difficulty with lubrica-
tion and orgasm. Prevention of end-organ 
complications may be important in preserving 
sexual activity and function in diabetic women. 
For the purposes of analysis, participants were 
categorized into one of three-diabetes status 
groups based on whether they had diabetes, 
and, if so, whether they were using insulin: (1) 
insulin-treated diabetic women, (2) non-insulin-
treated diabetic women, and (3) non-diabetic 
women. These categories were chosen a priori 
based on the recognition that insulin use is a 
widely recognized indicator of diabetes severity 
and represents a higher level of disease man-
agement burden that can interfere with day-to-
day functioning and quality of life. 
Differences in the demographic and clinical 
characteristics of participants in these three cat-
egories were examined using chi-square tests 
for categorical variables and analysis of covari-
ance for continuous variables. Next, it is de-
scribed the distribution of less than monthly 
sexual activity, less than moderate sexual desire, 
and less than moderate sexual satisfaction 
among women in each diabetes status category. 
Among women reporting at least some sexual 
activity in the past 3 months, the prevalence of 
specific sexual problems such as low or very 
low arousal, at least moderate difficulty with lu-
brication, at least moderate difficulty with or-
gasm, or at least moderate pain with vaginal in-
tercourse were also examined among women in 
each diabetes status category. Differences in the 
distribution of these sexual function outcomes 
among women in different diabetes status cate-
gories were examined using chi-square tests. 
Multivariable logistic regression models com-
pared sexual function outcomes among: (1) in-
sulin-treated diabetic versus nondiabetic wom-
en, and (2) noninsulin-treated diabetic versus 
nondiabetic women, adjusting for a core set of 
other factors with potential to influence sexual 
function (i.e., age, race/ethnicity, mari-
tal/relationship status, menopausal status, his-
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tory of sex with men or women, body mass in-
dex, hysterectomy and oophorectomy, selective 
serotonin reuptake inhibitor [SSRI] use, and es-
trogen use.) While models examining frequency 
of sexual activity, desire, and satisfaction in-
cluded all women, models examining specific 
sexual problems were confined to sexually ac-
tive women, and additionally controlled for fre-
quency of sexual activity. 
Sexual activity, desire, and satisfaction out-
comes were examined in all diabetic partici-
pants, while specific problems with lubrication, 
arousal, orgasm, or pain were examined in sex-
ually active diabetic women only.  
Of the 2,270 participants, 139 (6.1%) were insu-
lin-treated diabetic, 347 (15.3%) were noninsu-
lin-treated diabetic, and 1,784 (78.6%) were 
non-diabetic women. Mean (± SD) age was 55 
(± 9.2) years, 1,006 (44.4%) were non-Latina 
white, 443 (19.5%) were African-American, 401 
(17.7%) were Latina, 401 (17.7%) were Asian, 
and 18 (0.8%) were Native American. Overall, 
63.7% of participants reported some sexual ac-
tivity in the past 3 months. Of the 807 women 
who reported no sexual activity in the past 3 
months, 271 (33.6%) indicated that lack of a 
partner and 224 (27.7%) indicated that partner 
health problems contributed to their sexual in-
activity. 
Insulin-treated diabetic women were less likely 
to report at least monthly sexual activity com-
pared to either non-insulin-treated diabetic 
women or non-diabetic women. Insulin-treated 
diabetic women were also more likely to report 
low sexual desire and satisfaction compared to 
non-insulin-treated diabetic women or non-
diabetic women (Nowosielski and Skrzypulec-
Plinta 2011, 2532–45). 
Among sexually active participants, problems 
with lubrication were also more common in in-
sulin-treated diabetic women compared to non-
diabetic women (Carati et al. 2013, 2668–74). 
Among sexually active women, insulin-treated 
diabetic women were also more than twice as 
likely to report difficulty with lubrication and 
80% more likely to report difficulty-achieving 
orgasm compared to non-diabetic women, after 
adjusting for the same demographic and clinical 
factors. When asked if their physical health lim-
ited their sexual activity, insulin-treated diabetic 
women were more likely than non-diabetic 
women to report that their health limited their 
sexual activity “quite a bit” or “extremely,” in 
multivariable analysis (OR[95%CI] = 
2.29[1.49–3.51]). However, non-insulin-treated 
diabetic women were not substantially more 
likely than non-diabetic women to feel that 
their health limited their sexual activity (OR 
[95% CI] = 1.29 [0.92–1.78]). 
Diabetic women with peripheral neuropathy 
were also more likely to report less than month-
ly sexual activity, lower sexual desire, and limi-
tation of sexual activity by physical health, 
compared to those without neuropathy. Among 
sexually active diabetic women, no significant 
associations between specific diabetic end-
organ complications and sexual problems such 
as difficulty with arousal, lubrication, orgasm, 
or pain with intercourse were observed in ad-
justed models. There were also no significant 
associations between number of years since di-
abetes diagnosis and sexual function, after ad-
justment for end-organ complications (P > 0.05 
for all). 
In this cohort of ethnically diverse middle-aged 
and older women, diabetic and non-diabetic 
women reported similar levels of sexual desire 
and frequency of sexual activity, after adjust-
ment for other demographic and clinical fac-
tors. However, both insulin-treated and non-
insulin-treated diabetic women were significant-
ly more likely to report low overall sexual satis-
faction compared to non-diabetic women, and 
problems with lubrication and orgasm were 
more common among insulin-treated diabetic 
women compared to nondiabetic women. 
These findings suggest that while many diabetic 
women are interested and engaged in sexual ac-
tivity, diabetes is associated with a markedly de-
creased sexual quality of life in women, either 
through complications of the disease itself or 
through utilization of treatments. 
This study underlines the importance of distin-
guishing between different aspects of female 
sexual function when evaluating the burden of 
this disease. Based on this research, diabetes 
and its complications appear to have a much 
greater impact on sexual problems such as lu-
brication and orgasm as opposed to sexual de-
sire or subjective arousal. Furthermore, our 
study indicates that the adverse effects of diabe-
tes on sexual function may be concentrated in 
women taking insulin, an apparently high-risk 
group for developing sexual problems. 
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Diabetic women who were less motivated or 
interested in checking and controlling their 
blood sugars may have placed more priority on 
sexual activity and/or function in their daily 
lives, resulting in higher reports of sexual satis-
faction. Alternatively, diabetic women with 
worse glycemic control may have had lower ex-
pectations about sexual activity in the setting of 
their poorly controlled disease, with the para-
doxical result that they retained a stronger sub-
jective sense of sexual satisfaction in spite of 
experiencing the same sexual difficulties. Dif-
ferences in impulse control and other unmeas-
ured personality factors could also have influ-
enced both glycemic control and sexual satis-
faction in diabetic participants. 
Based on this research, clinicians may want to 
consider actively assessing for sexual problems 
in diabetic women, particularly those taking in-
sulin, and counsel diabetic women that preven-
tion of end-organ complications may be im-
portant in preserving their sexual function 
(Copeland et al. 2012, 331–40). 
In Jordanian’s study women were grouped into 
a diabetic married group (n = 613) and a nondi-
abetic married group (n = 524). The age of dia-
betic women ranged from 23 to 68 years (mean 
± SD 46 ± 11 years), and the age of nondiabet-
ic women ranged from 22 to 70 (51 ± 10 years). 
The prevalence of FSD in diabetic women 50 
years of age or older was significantly higher 
compared with that in nondiabetic women. De-
sire, arousal, lubrication, and orgasm were more 
significantly affected in older diabetic women, 
whereas in younger women a significant differ-
ence was only found in desire. Multivariate 
analysis showed that glycemic control, type of 
diabetes, smoking, hypertension, dyslipidemia, 
and peripheral and autonomic neuropathy did 
not have a significant effect on FSD. On the 
other hand, longer duration of diabetes, older 
age, higher BMI, and the presence of coronary 
artery disease, nephropathy, and retinopathy 
had significant detrimental effects on female 
sexual function. This study shows that diabetic 
women in Jordan have more FSD than nondi-
abetic women. The prevalence of FSD in our 
study is in agreement with the global prevalence 
(Erol et al. 2002, 55–62) Neurovascular pro-
cesses that mediate genital vasocongestion are 
impaired in diabetes (Meston and Frohlich 
2001, 603–9) In this study, vaginal dryness was 
found significantly more often-in diabetic 
women than in nondiabetic women. Orgasmic 
dysfunction was more prevalent in older diabet-
ic women in comparison with their nondiabetic 
counterparts. Kolodny reported a higher fre-
quency of orgasmic dysfunction in diabetic 
women than in hospitalized women for various 
reasons (Enzlin et al. 2002, 672–77). 
However, diabetic women were less satisfied 
with their sexual life. This is in agreement with 
the findings of Enzlin et al (Abu Ali et al. 2008, 
1580–81).  
Neuropathy, vascular impairment, and psycho-
logical complaints have been implicated in the 
pathogenesis of decreased libido, low arousabil-
ity, decreased vaginal lubrication, orgasmic dys-
function, and dyspareunia among diabetic 
women. A cross-sectional study was conducted 
on 500 women who were recruited from a dia-
betes center, based on questionnaires complet-
ed by them. Data regarding demographic fea-
tures, physical complications, and sexual disor-
ders were obtained. Medical records of patients 
were used to obtain body mass index (BMI) 
and details of complications. Mean age of par-
ticipants, duration of diabetes, and BMI was 
48.8 ± 0.4, 8.9 ± 0.32 years, and 28.9 ± 0.23, 
respectively. Prevalence of sexual dysfunction 
was 32.3%. Low sexual desire was seen in 
81.8%, disorders of arousal in 78.3%, of or-
gasm in 47.5%, and 35.1% had disorder in reso-
lution area. There was no significant relation-
ship between some factors such as age, dura-
tion of diabetes, BMI, and frequency of sexual 
dysfunction. Frequency of diabetic complica-
tions demonstrated a significant effect on the 
prevalence of sexual dysfunction. Sexual prob-
lems are frequent among diabetic women and 
deserve more attention in clinical practice and 
researches.  
In a research conducted by Amini et al 
(Omidvar et al. 2013, 321–24) in Isfahan in 
2001, a low sexual desire, lack of sexual satisfac-
tion, low vaginal lubrication, and orgasmic dys-
function have been recognized as sexual prob-
lems among women. For every patient with di-
abetes who refers with a reduction in sexual de-
sire, first other reasons (hormonal reasons and 
so on) should be ruled out, and then neuro-
pathic; therefore, the genital organ should be 
examined, and the levels of testosterone, pro-
lactin, thyrotropin, and estrogen should be 
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checked. Sexual dysfunction among women 
with diabetes includes vaginal dryness, a low 
sense of perinea, a lack of orgasm, and so on. 
The average age of the subjects, duration of 
married life, number of children, duration of 
diabetes, and body mass index (BMI) were 48.8 
± 0.04 years, 29.6 ± 0.5 years, 4.2 ± 0.1, 8.9 ± 
0.3 years, and 28.9 ± 0.2, respectively. The re-
sults show a significant frequency of sexual dys-
function in different sexual areas. Majority 
(95%) of the subjects were suffering from type 
2 diabetes; 26.3% of them mentioned a severe 
pain during sexual intercourse. In this study, 
there was no association between age, diabetes 
duration, and BMI with frequency of sexual 
dysfunction, although there was a significant 
association between age and dysfunction in de-
sire (P = 0.02), sexual satisfaction (P = 0.01), 
and pain during intercourse (P = 0.004). It is 
found a significant statistical association be-
tween the number of complications due to dia-
betes and frequency of sexual dysfunction (P = 
0.01). Overall, sexual dysfunction among wom-
en with diabetes was 32.3%. Nearly 82% of 
them were afflicted in the area of dysfunction 
in sexual desire, 78.3% had problems of arous-
al, 47.5% experienced dysfunction in orgasm, 
and 35.1% in the area of resolution. In all, 
45.5% were not satisfied with sexual function-
ing. 39.4% experienced pain during intercourse, 
and 36.1% had disorders in vaginal lubrication. 
Previous reports have shown an increase in the 
prevalence of sexual dysfunction among wom-




Diabetic women with end-organ complications 
such as peripheral neuropathy, renal dysfunc-
tion, stroke and heart disease were more likely 
to report decreased sexual activity or lower sex-
ual satisfaction than diabetic women without 
these complications. 
Several studies suggest the presence of sexual 
dysfunction among those who suffer from type 
two diabetes (Omidvar et al. 2013, 321–24; Bul-
trini et al. 2004, 337–40). These disorders in-
clude disorders of desire, lubrication, satisfac-
tion, orgasm, and dyspareunia. The etiology of 
sexual dysfunction in patients with diabetes 
needs more attention because patients with dia-
betes are at risk for vascular and psychological 
complications. Therefore, they have a higher 
risk for developing sexual dysfunction (Fatemi 
and Taghavi 2009, 38–39). 
These findings suggest that diabetic end-organ 
complications may play an important role in 
decreasing women’s sexual quality of life, and 
that raise the possibility that prevention of dia-
betic complications may be helpful in prevent-
ing sexual dysfunction in women with diabetes. 
 
The steps to be taken are clear: campaigns 
aimed at  
(1) Prevention of type 2 diabetes 
(2) Screening for early diabetic disease 
(3) Increasing patient awareness of vulvovaginal 
disease 
(4) Using medications of proven strategy and 
finally  
(5) Researching and trialing of new therapies.  
 
The ultimate challenge is to get action from 
primary health care to all higher levels; from the 
individual patient, to those at risk, in various 
health jurisdictions, in all countries despite 
varying economic circumstances and priorities. 
The problem is a global one and yet requires 
action at a local level; prevention, screening, 
and treatment strategies; education, including 
increasing awareness both in diabetic patients 
and those at risk of developing diabetes; and 
health priorities of governments. Basic research 
and clinical trials searching for a new under-
standing and therapies must be supported. It is 
time for strategies that prevent diabetes and its 
sequelae. It is time for programs for health care 
workers to diagnose and treat people with dia-
betic vulvovaginal disease, starting from basic 
hygiene that should be practiced with specific 
product, with specific active addressed to im-
prove moisturisation, lubrication of the intimate 
area and able to exert a soothing action in case 
of irritability and itching. 
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